Bioventus vs Glaukos
Bioventus and Glaukos are similar in size: $568m and $507m of revenue in their latest fiscal years. Glaukos grew faster (32.3% against -0.9%). Bioventus kept more of each dollar of sales as profit: a net margin of 4.0% against -37.0%. Glaukos carries less debt relative to equity (0.0% against 159.7%).
| Latest fiscal year | BioventusBVS, 2025 | GlaukosGKOS, 2025 |
|---|---|---|
| Revenue | $568m | $507m |
| Revenue growth | -0.9% | 32.3% |
| Net income | $22.7m | −$188m |
| Operating margin | 9.5% | -39.3% |
| Net margin | 4.0% | -37.0% |
| Return on equity | 13.7% | -26.4% |
| Free cash flow | $72.1m | −$22.5m |
| Cash | $51.2m | $90.8m |
| Total debt | $294m | $0 |
| Debt to equity | 159.7% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 930 | 1,094 |
| Market value | $795m | $14.03bn |
| Price vs our value range | Within our value range | — |
| Moat score | 43 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 0 buys, 3 sales | 0 buys, 61 sales |